Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 19 Aug 2024 |
| Genmab Announces Changes to its Executive Committee | 16 Aug 2024 |
| Genmab A/S has published its Articles of Association | 14 Aug 2024 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 13 Aug 2024 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 13 Aug 2024 |
| Genmab Updates 2024 Financial Guidance | 8 Aug 2024 |